RETA
Closed
Reata Pharmaceuticals Inc
172.36
+0.04 (+0.02%)
Last Update: 26 Sep 2023 16:30:00
Yesterday: 172.32
Day's Range: 172.36 - 172.36
Send
sign up or login to leave a comment!
When Written:
93.98
Reata Pharmaceuticals Inc. is a biopharmaceutical company that develops and commercializes innovative therapies for serious and rare diseases. The company was founded in 2002 and is headquartered in Irving, Texas.
Reata's lead product candidate is bardoxolone methyl, a potential treatment for various chronic diseases such as chronic kidney disease, pulmonary arterial hypertension, and Alport syndrome. The company also has a pipeline of other drug candidates in various stages of development, including omaveloxolone for Friedreich's ataxia and neurological disorders, and RORγt inhibitors for autoimmune diseases.
Reata has partnerships with various pharmaceutical companies, including Kyowa Kirin Co. Ltd., AbbVie Inc., and Blackstone Life Sciences. The company has received funding from various sources, including venture capital firms, public offerings, and grants from the National Institutes of Health.
Reata is committed to advancing the development of innovative therapies for patients with unmet medical needs.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Reata's lead product candidate is bardoxolone methyl, a potential treatment for various chronic diseases such as chronic kidney disease, pulmonary arterial hypertension, and Alport syndrome. The company also has a pipeline of other drug candidates in various stages of development, including omaveloxolone for Friedreich's ataxia and neurological disorders, and RORγt inhibitors for autoimmune diseases.
Reata has partnerships with various pharmaceutical companies, including Kyowa Kirin Co. Ltd., AbbVie Inc., and Blackstone Life Sciences. The company has received funding from various sources, including venture capital firms, public offerings, and grants from the National Institutes of Health.
Reata is committed to advancing the development of innovative therapies for patients with unmet medical needs.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








